Thursday, April 21, 2011
Marina Biotech Inc., of Bothell, Wash., completed enrollment of its first cohort in its START-FAP Phase Ib/IIa trial of CEQ508, an attenuated bacteria engineered to deliver shRNA, for familial adenomatous polyposis. The cohort of three patients will receive the lowest dose as a daily drink for 28 days.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.